Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials

Ladanie, Aviv and Ioannidis, John P. A. and Stafford, Randall S. and Ewald, Hannah and Bucher, Heiner C. and Hemkens, Lars G.. (2018) Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials. Journal of clinical epidemiology, 94. pp. 35-45.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/60977/

Downloads: Statistics Overview


Off-label drug use is highly prevalent but controversial and often discouraged assuming generally inferior medical effects associated with off-label use.; We searched PubMed, MEDLINE, PubMed Health, and the Cochrane Library up to May 2015 for systematic reviews including meta-analyses of randomized clinical trials (RCTs) comparing off-label and approved drugs head-to-head in any population and on any medical outcome. We combined the comparative effects in meta-analyses providing summary odds ratios (sOR) for each treatment comparison and outcome, and then calculated an overall summary of the sOR across all comparisons (ssOR).; We included 25 treatment comparisons with 153 RCTs and 24,592 patients. In six of 25 comparisons (24%), off-label drugs were significantly superior (five of 25) or inferior (one of 25) to approved treatments. There was substantial statistical heterogeneity across comparisons (I2 = 43%). Overall, off-label drugs were more favorable than approved treatments (ssOR 0.72; 95% CI = 0.54-0.95). Analyses of patient-relevant outcomes were similar (statistical significant differences in 24% (six of 25); ssOR 0.74; 95% CI = 0.56-0.98; I2 = 60%). Analyses of primary outcomes of the systematic reviews (n = 22 comparisons) indicated less heterogeneity and no statistically significant difference overall (ssOR 0.85; 95% CI = 0.67-1.06; I2 = 0%).; Approval status does not reliably indicate which drugs are more favorable in situations with clinical trial evidence comparing off-label with approved use. Drug effectiveness assessments without considering off-label use may provide incomplete information. To ensure that patients receive the best available care, funding, policy, reimbursement, and treatment decisions should be evidence based considering the entire spectrum of available therapeutic choices.
Faculties and Departments:09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH)
UniBasel Contributors:Ladanie, Aviv and Ladanie, Aviv and Ewald, Hannah
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Pergamon Press
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:27 Jun 2018 09:35
Deposited On:27 Jun 2018 09:35

Repository Staff Only: item control page